Biodexa Announces 1-for-8 Reverse ADS Split Effective October 26
Summary
Biodexa is implementing a 1-for-8 reverse ADS split effective October 26, 2026, changing the ADS ratio from 1:50 to 1:400 ordinary shares. The move is designed to raise the ADS trading price and maintain Nasdaq listing compliance.
Key Events · Corporate Governance and Compliance · BDRX
-
1-for-8 Reverse ADS Split Announced
ADS ratio changes from 1 ADS = 50 ordinary shares to 1 ADS = 400 ordinary shares, effective on or about October 26, 2026. Every 8 old ADSs (CUSIP 59564R872) will be exchanged for 1 new ADS (CUSIP 59564R864).
-
Ordinary Shares Unaffected
The ratio change applies only to ADSs; the underlying ordinary shares are not altered. No fractional ADSs will be issued — fractional interests will be sold and net proceeds distributed to holders.
-
Listing Compliance Context
The reverse ADS split follows a 1-for-10,000 reverse split of ordinary shares approved July 29, 2026, and comes amid a going-concern warning with £3.23 million cash at June 30, 2026. The move is aimed at lifting the ADS price above Nasdaq's minimum bid threshold.
-
Mandatory Exchange Process
JPMorgan Chase Bank, N.A., as depositary, will contact ADS holders to arrange the mandatory surrender and exchange of old ADSs for new ADSs.
Analysis · BDRX · Life Sciences
Biodexa is changing its ADS ratio from 1 ADS representing 50 ordinary shares to 1 ADS representing 400 ordinary shares, effective on or about October 26, 2026. For ADS holders, this has the same effect as a one-for-eight reverse ADS split — every 8 old ADSs will be mandatorily exchanged for 1 new ADS. The ordinary shares themselves are not affected. This is a compliance-driven move to lift the ADS price above Nasdaq's minimum bid requirement, coming just weeks after shareholders approved a 1-for-10,000 reverse split of the ordinary shares and amid a going-concern warning with only £3.23 million in cash at June 30, 2026.
How filings like this one have moved
In the 30 days to Oct 14, 2026, 29.1% of the 1502 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.50%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BDRX was trading at $0.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $360.4K. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.